H1 2019 revenue was 130 million. The new formula was not released until early FEB 2019. So effectively lost 6 weeks of sales. 2019 guidance 275-300m. Therefore I don't expect significant earnings upgrade without SAMR.
BAL Price at posting:
$9.04 Sentiment: Hold Disclosure: Held